Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center, Presbyterian - St. Luke's Medical Center
Keywords/Phrases:  gastrointestinal cancer
Trial Status:  Active
Results 1-25 of 66 for your search:
Start Over
Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: N1048, NCCTG-N1048, CDR0000715321, NCI-2012-00234, U10CA031946, NCT01515787
S0820, Adenoma and Second Primary Prevention Trial
Phase: Phase III
Type: Prevention
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S0820, U10CA037429, NCI-2012-02067, NCT01349881
S1202: Duloxetine Hydrochloride to Treat Muscle, Bone, and Joint Pain in Pts W/Early-Stage Breast Cancer Receiving Hormone Therapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: S1202, U10CA037429, NCI-2012-01960, SWOG-S1202, NCT01598298
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000675693, CALGB-80702, CALGB-SWOG-C80702, NCT01150045
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2011-01975, CDR0000654889, COG-AHEP0731, AHEP0731, U10CA180886, U10CA098543, NCT00980460
Collecting and Storing Tissue From Young Patients With Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Tissue collection/Repository
Status: Active
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: ABTR04B1, COG-ABTR04B1, NCI-2009-00326, NCT00898755
S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S1406, U10CA180888, NCI-2014-00814, NCT02164916
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00587, CDR0000546714, GOG-0213, U10CA180868, U10CA027469, NCT00565851
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01985, U10CA021115, ECOG-E2511, CDR0000736704, E2511, U10CA180820, NCT01642251
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
Phase: Phase II
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: SCUSF 0806, 5U10CA081920-11, HLMCC-0806, NCT01009918
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 19 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00629, GOG-0281, U10CA180868, U10CA027469, NCT02101788
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-01509, A151216, U10CA180821, U10CA031946, NCT02194738
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000588879, CALGB-30610, RTOG 0538, U10CA031946, NCT00632853
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-01508, A081105, U10CA180821, U10CA031946, NCT02193282
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: E2211, NCI-2012-02007, U10CA021115, U10CA180820, NCT01824875
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-02228, NSABP B-52, U10CA012027, U10CA180868, NCT02003209
Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00746, ECOG-E2112, E2112, U10CA180820, U10CA021115, NCT02115282
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02623, CDR0000692475, SWOG-S1007, S1007, U10CA180888, U10CA032102, NCT01272037
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 0 to 75
Sponsor: NCI, Other
Protocol IDs: 2546.00, NCI-2011-03828, P30CA015704, P01CA018029, NCT01527045
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Phase: No phase specified
Type: Tissue collection/Repository
Status: Active
Age: 0 months to 30 year
Sponsor: NCI, Other
Protocol IDs: ABTR01B1, NCI-2009-00324, COG-ABTR01B1, U10CA098543, NCT00898079
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 2206.00, NCI-2010-02222, P30CA015704, P01CA018029, NCT01251575
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S1207, U10CA032102, NCI-2012-01995, SWOG-S1207, NCT01674140
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III
Type: Behavioral study, Biomarker/Laboratory analysis
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: GOG-0225, NCI-2009-00595, CDR0000594600, U10CA101165, UG1CA189867, NCT00719303
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: NCI-2011-02670, COG-AAML1031, CDR0000701850, AAML1031, U10CA180886, U10CA098543, NCT01371981
Start Over